Storage Security

TICEBA guarantees maximal protection and security for the stem cells stored in our "Bio-Safe" as well as quick availability at any time.

TICEBA - Storage Security


Laboratory Analyses

In the context of storage, we arrange for many different examinations with regard to possible viral infections on a blood sample obtained from you. This is to guarantee the health of your stem cells from the very beginning.

In addition, the skin tissue with the stem cells contained therein is obtained by a physician in surgical sterile conditions. Any further steps also take place in sterile conditions. 


Gentle Conservation

The freezing procedure is carried out by specific computer-operated equipment, which gently conserves the skin cells as well as the valuable stem cells.


Secure Storage

The stem cells are stored in special cryotanks with liquid nitrogen. Storage is exclusively carried out in the gaseous phase. Our cryotanks work independently from electric power supply. Nitrogen supply for the cooling system is therefore guaranteed failsafe around the clock.


Secrecy and Data Protection

We are of course subject to patient/physician confidentiality and data protection. We guarantee absolute confidentiality of the information stored with us. Your stored tissue is only available to yourself exclusively . No one but you may dispose of the material.

News
Coronavirus and Mesenchymal Stem Cells

Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus

Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus

Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter